-
-
-
-
-
-
-
BioMarin Reports First Quarter 2026 Financial and Operating Results
-
-
-
-
-
-
-
BioMarin closes $850 million senior notes offering for Amicus acquisition
-
-
-
-
-
-
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $100 at Truist Securities
-
-
-
-
-
-
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $95 at Bernstein SocGen Group
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN) Following Inozyme Deal
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Appoints Mark Alles to its Board
-
1,178,436 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

